CFD merupakan instrumen yang rumit dan memiliki risiko tinggi kehilangan uang secara cepat karena adanya pengaruh leverage. 84% akun investor ritel mengalami kerugian saat melakukan kegiatan perdagangan CFD dengan penyedia ini. Anda harus mempertimbangkan apakah Anda memahami cara kerja CFD dan apakah Anda mampu menerima risiko tinggi kehilangan uang.

Scan to Download iOS&Android APP

Perdagangan Teva Pharma Ind Adr Rep 1 - TEVA CFD

10.68
0.09%
0.09
Rendah: 10.64
Tinggi: 10.73
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.09
Biaya inap posisi Long

Long position overnight fee


Margin. Your investment $1,000.00
Biaya Overnight -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Kunjungi platform
-0.030779%
Biaya inap posisi short

Short position overnight fee


Margin. Your investment $1,000.00
Biaya Overnight -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Kunjungi platform
-0.013666%
Waktu biaya inap 22:00 (UTC)
Kuantitas min. yang diperdagangkan 1
Mata uang USD
Margin 20%
Bursa efek United States of America
Komisi perdagangan 0%

*Information provided by Capital.com

Teva Pharmaceutical Industries Ltd ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

Key Stats
Prev. Close* 10.67
Open* 10.66
1-Year Change* 25.56%
Day's Range* 10.64 - 10.73
52 wk Range 6.78-11.45
Average Volume (10 days) 8.25M
Average Volume (3 months) 194.23M
Market Cap 11.79B
P/E Ratio -100.00K
Shares Outstanding 1.11B
Revenue 15.14B
EPS -1.17
Dividend (Yield %) N/A
Beta 1.21
Next Earnings Date Feb 8, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 6, 2023 10.68 0.00 0.00% 10.68 10.74 10.61
Feb 3, 2023 10.67 0.16 1.52% 10.51 10.76 10.51
Feb 2, 2023 10.66 0.09 0.85% 10.57 10.68 10.47
Feb 1, 2023 10.56 0.11 1.05% 10.45 10.64 10.35
Jan 31, 2023 10.39 0.18 1.76% 10.21 10.67 10.21
Jan 30, 2023 10.21 0.07 0.69% 10.14 10.36 10.05
Jan 27, 2023 10.24 0.10 0.99% 10.14 10.48 10.14
Jan 26, 2023 10.23 0.09 0.89% 10.14 10.27 10.07
Jan 25, 2023 10.15 0.11 1.10% 10.04 10.19 10.02
Jan 24, 2023 10.05 -0.16 -1.57% 10.21 10.32 10.05
Jan 23, 2023 10.33 0.02 0.19% 10.31 10.43 10.20
Jan 20, 2023 10.21 -0.30 -2.85% 10.51 10.59 10.21
Jan 19, 2023 10.47 0.00 0.00% 10.47 10.62 10.23
Jan 18, 2023 10.80 0.00 0.00% 10.80 10.90 10.68
Jan 17, 2023 10.95 -0.15 -1.35% 11.10 11.21 10.92
Jan 13, 2023 11.18 -0.01 -0.09% 11.19 11.27 10.94
Jan 12, 2023 11.26 0.19 1.72% 11.07 11.41 11.02
Jan 11, 2023 10.96 0.02 0.18% 10.94 11.14 10.82
Jan 10, 2023 10.88 0.06 0.55% 10.82 11.01 10.75
Jan 9, 2023 10.78 -0.05 -0.46% 10.83 11.19 10.58

Teva Pharma Ind Adr Rep 1 Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 21903 22385 18854 16887 16659 15878
Revenue 21903 22385 18854 16887 16659 15878
Cost of Revenue, Total 10250 11770 10558 9351 8870 8014
Gross Profit 11653 10615 8296 7536 7789 7864
Total Operating Expense 20631 39911 20537 17330 20231 14162
Selling/General/Admin. Expenses, Total 4973 4637 4052 3667 3519 3402
Research & Development 2077 1778 1213 1010 997 967
Unusual Expense (Income) 3286 21520 4838 3191 6739 1721
Other Operating Expenses, Total 45 -3 -286 -28 -20 -41
Operating Income 1272 -17526 -1683 -443 -3572 1716
Interest Income (Expense), Net Non-Operating -446 -856 -894 -825 -833 -988
Other, Net -2 3 -19 3 -1 -70
Net Income Before Taxes 824 -18379 -2596 -1265 -4406 658
Net Income After Taxes 303 -17507 -2304 -987 -4238 447
Minority Interest 18 184 322 2 109 -39
Equity In Affiliates 8 -3 -71 -13 138 9
Net Income Before Extra. Items 329 -17326 -2053 -998 -3991 417
Total Extraordinary Items 0 1061 -97 0 0
Net Income 329 -16265 -2150 -998 -3991 417
Total Adjustments to Net Income -261 -260 -249 -1 1
Income Available to Common Excl. Extra. Items 68 -17586 -2302 -999 -3990 417
Income Available to Common Incl. Extra. Items 68 -16525 -2399 -999 -3990 417
Dilution Adjustment 0
Diluted Net Income 68 -16525 -2399 -999 -3990 417
Diluted Weighted Average Shares 961 1016 1021 1091 1095 1107
Diluted EPS Excluding Extraordinary Items 0.07076 -17.3091 -2.25465 -0.91567 -3.64384 0.37669
Dividends per Share - Common Stock Primary Issue 1.36 0.85 0
Diluted Normalized EPS 2.29537 -3.51127 0.82537 0.98547 0.35648 1.43282
Depreciation / Amortization 209 162 139 126 99
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 3982 3910 3887 4100 3661
Revenue 3982 3910 3887 4100 3661
Cost of Revenue, Total 2063 1987 1989 1975 1859
Gross Profit 1919 1923 1898 2125 1802
Total Operating Expense 3548 3328 3264 4022 4374
Selling/General/Admin. Expenses, Total 848 832 864 858 819
Research & Development 254 243 222 249 225
Depreciation / Amortization 27 25 24 23 22
Unusual Expense (Income) 360 247 183 893 1502
Other Operating Expenses, Total -4 -6 -18 24 -53
Operating Income 434 582 623 78 -713
Interest Income (Expense), Net Non-Operating -381 -254 -254 -170 -238
Other, Net 91 -20 13 -83 -20
Net Income Before Taxes 144 308 382 -175 -971
Net Income After Taxes 82 210 306 -151 -973
Minority Interest -7 -14 -11 -7 -3
Equity In Affiliates 3 11 -5 0 21
Net Income Before Extra. Items 78 207 290 -158 -955
Net Income 78 207 290 -158 -955
Total Adjustments to Net Income -1 2 -1
Income Available to Common Excl. Extra. Items 77 207 292 -159 -955
Income Available to Common Incl. Extra. Items 77 207 292 -159 -955
Diluted Net Income 77 207 292 -159 -955
Diluted Weighted Average Shares 1107 1109 1109 1102 1107
Diluted EPS Excluding Extraordinary Items 0.06956 0.18665 0.2633 -0.14428 -0.86269
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.25474 0.33851 0.39548 0.38244 0.01924
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 17228 15382 13794 13464 13005 12573
Cash and Short Term Investments 1667 977 1784 1975 2177 2165
Cash & Equivalents 988 963 1782 1975 2177 2165
Short Term Investments 679 14 2
Total Receivables, Net 7523 7128 5822 5676 4581 4529
Accounts Receivable - Trade, Net 7523 7128 5822 5676 4581 4529
Total Inventory 4954 4924 4731 4422 4403 3818
Prepaid Expenses 1629 1100 899 870 945 1075
Other Current Assets, Total 1455 1253 558 521 899 986
Total Assets 93057 70615 60683 57470 50640 47666
Property/Plant/Equipment, Total - Net 8073 7673 6868 6950 6855 6477
Property/Plant/Equipment, Total - Gross 11926 12178 11796 11864 11947 11718
Accumulated Depreciation, Total -3853 -4505 -4928 -4914 -5092 -5241
Goodwill, Net 44409 28414 24917 24846 20624 20040
Intangibles, Net 21487 17640 14005 11232 8923 7466
Other Long Term Assets, Total 1860 1423 1038 978 1233 1110
Total Current Liabilities 18488 17921 14322 13674 13164 11027
Accounts Payable 2157 2069 1853 1718 1756 1686
Accrued Expenses 4264 3563 2738 2680 2581 2880
Notes Payable/Short Term Debt 2466 766 516 514 514 23
Current Port. of LT Debt/Capital Leases 810 2880 1700 1831 2674 1403
Other Current Liabilities, Total 8791 8643 7515 6931 5639 5035
Total Liabilities 59720 53256 45976 43498 40614 37388
Total Long Term Debt 32522 28827 26691 24562 22731 21617
Long Term Debt 32522 28827 26691 24562 22731 21617
Deferred Income Tax 5413 3277 2140 1096 964 784
Minority Interest 1656 1386 1087 1091 1035 966
Other Liabilities, Total 1641 1845 1736 3075 2720 2994
Total Equity 33337 17359 14707 13972 10026 10278
Redeemable Preferred Stock 3620 3631 0
Common Stock 54 54 56 56 57 57
Additional Paid-In Capital 23409 23479 27210 27312 27443 27561
Retained Earnings (Accumulated Deficit) 13607 -3803 -5958 -6956 -10946 -10529
Treasury Stock - Common -4194 -4149 -4142 -4128 -4128 -4128
Unrealized Gain (Loss) -7 -4 1 0 0 0
Other Equity, Total -3152 -1849 -2460 -2312 -2400 -2683
Total Liabilities & Shareholders’ Equity 93057 70615 60683 57470 50640 47666
Total Common Shares Outstanding 1014.99 1016.88 1089.39 1092.19 1096.51 1103.33
Total Preferred Shares Outstanding 3.7 3.7 0 0 0
Long Term Investments 83 61
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 12401 12822 12154 12573 12451
Cash and Short Term Investments 1743 2436 2045 2165 2175
Cash & Equivalents 1743 2436 2045 2165 2175
Total Receivables, Net 4572 4488 4046 4529 4253
Accounts Receivable - Trade, Net 4572 4488 4046 4529 4253
Total Inventory 4406 4362 4167 3818 4012
Prepaid Expenses 942 1022 1066 1075 1064
Other Current Assets, Total 738 514 830 986 947
Total Assets 49004 49195 47851 47666 47059
Property/Plant/Equipment, Total - Net 6641 6658 6547 6477 6396
Goodwill, Net 20302 20421 20179 20040 19986
Intangibles, Net 8445 8120 7832 7466 7116
Other Long Term Assets, Total 1215 1174 1139 1110 1110
Total Current Liabilities 12089 12691 11825 11027 11613
Accounts Payable 1692 1551 1514 1686 1750
Accrued Expenses 2377 2318 2590 2771 3078
Notes Payable/Short Term Debt 23 23 323 23 23
Current Port. of LT Debt/Capital Leases 2674 3507 2386 1403 2054
Other Current Liabilities, Total 5323 5292 5012 5144 4708
Total Liabilities 39004 38871 37384 37388 37715
Total Long Term Debt 22288 21602 21037 21617 20840
Long Term Debt 22288 21602 21037 21617 20840
Deferred Income Tax 991 932 910 784 666
Minority Interest 975 987 984 966 916
Other Liabilities, Total 2661 2659 2628 2994 3680
Total Equity 10000 10324 10467 10278 9344
Common Stock 57 57 57 57 57
Additional Paid-In Capital 27474 27503 27529 27561 27587
Retained Earnings (Accumulated Deficit) -10869 -10662 -10370 -10529 -11484
Treasury Stock - Common -4128 -4128 -4128 -4128 -4128
Other Equity, Total -2534 -2446 -2621 -2683 -2688
Total Liabilities & Shareholders’ Equity 49004 49195 47851 47666 47059
Total Common Shares Outstanding 1102.35 1102.89 1103.01 1103.33 1110.35
Total Preferred Shares Outstanding 0
Unrealized Gain (Loss) 0
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 311 -16449 -2472 -1000 -4099 456
Cash From Operating Activities 3890 2225 2446 748 1216 798
Cash From Operating Activities 1524 2112 1842 1722 1557 1330
Deferred Taxes 15 -2331 -837 -985 -696 -120
Non-Cash Items 2156 20538 5736 1907 6642 833
Cash Taxes Paid 341 106 420 552 709 495
Cash Interest Paid 290 795 815 840 846 913
Changes in Working Capital -116 -1645 -1823 -896 -2188 -1701
Cash From Investing Activities -34405 3446 1866 1355 863 1523
Capital Expenditures -901 -874 -651 -525 -578 -562
Other Investing Cash Flow Items, Total -33504 4320 2517 1880 1441 2085
Cash From Financing Activities 25217 -5750 -3351 -1926 -1885 -2172
Financing Cash Flow Items -169 -112 -57 -11 -5 -6
Total Cash Dividends Paid -1558 -1161 -22 -52 0 0
Issuance (Retirement) of Stock, Net 693 0 0
Issuance (Retirement) of Debt, Net 26251 -4477 -3272 -1863 -1880 -2166
Foreign Exchange Effects -660 54 -142 16 8 -128
Net Change in Cash -5958 -25 819 193 202 21
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 84 306 608 456 -952
Cash From Operating Activities -405 -187 342 798 -49
Cash From Operating Activities 376 681 1010 1330 323
Deferred Taxes -11 5 13 -120 -175
Non-Cash Items 222 500 592 833 196
Changes in Working Capital -1076 -1679 -1881 -1701 559
Cash From Investing Activities 508 989 1277 1523 161
Capital Expenditures -150 -263 -409 -562 -157
Other Investing Cash Flow Items, Total 658 1252 1686 2085 318
Cash From Financing Activities -493 -494 -1671 -2172 2
Financing Cash Flow Items -2 -3 -5 -6 2
Issuance (Retirement) of Debt, Net -491 -491 -1666 -2166 0
Foreign Exchange Effects -44 -49 -80 -128 -62
Net Change in Cash -434 259 -132 21 52
Total Cash Dividends Paid 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Capital Research Global Investors Investment Advisor 10.5524 117190328 24024045 2022-09-30 LOW
Capital World Investors Investment Advisor 3.5415 39329765 39329765 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.8455 31600577 -827744 2022-09-30 LOW
Abrams Capital, L.L.C. Hedge Fund 2.152 23899296 -147060 2022-09-30
Menora Mivtachim Insurance Ltd. Insurance Company 2.0987 23307560 -3050 2022-09-30 LOW
Migdal Insurance and Financial Holdings Ltd Insurance Company 1.9447 21596560 216360 2022-12-31 MED
Phoenix Holdings Ltd Holding Company 1.8757 20831080 2301291 2022-09-30 MED
Clal Insurance Enterprises Holdings Ltd. Investment Advisor 1.7475 19406766 444000 2022-09-30 LOW
Harel Insurance Investments and Financial Services Ltd Investment Advisor 1.3613 15118229 985502 2022-12-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.3418 14901933 1055920 2022-09-30 LOW
EXOR Investments (UK) LLP Investment Advisor 1.0375 11522187 11522187 2022-09-30 LOW
Capital International Investors Investment Advisor 0.9613 10675231 -7647 2022-09-30 LOW
Miller Value Partners, LLC Investment Advisor 0.8334 9254875 -79715 2022-09-30 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.7338 8148857 126299 2022-09-30 LOW
Two Sigma Investments, LP Hedge Fund 0.7189 7983801 5844332 2022-09-30 HIGH
Beck, Mack & Oliver LLC Investment Advisor 0.6787 7536985 1072190 2022-09-30 LOW
Camber Capital Management LP Hedge Fund 0.6753 7500000 4750000 2022-09-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5973 6633114 314715 2022-09-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.4259 4730246 -881152 2022-09-30 LOW
Schweizerische Nationalbank Bank and Trust 0.4247 4716093 27700 2022-09-30 LOW

Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.

Capital.com Group
+485000+

Trader

65000+

Klien aktif per bulan

$48000000+

Volume investasi per bulan

$28000000+

Penarikan tiap bulan

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long
Industry: Pharmaceuticals (NEC)

5 Bazel St
P O B 3190
PETAH TIKVA
49131
IL

Income Statement

  • Annual
  • Quarterly

People also watch

BTC/USD

22,969.80 Price
+0.100% 1D Chg, %
Biaya inap posisi Long -0.0500%
Biaya inap posisi short 0.0140%
Waktu biaya inap 22:00 (UTC)
Spread 66.00

Oil - Crude

75.39 Price
+0.960% 1D Chg, %
Biaya inap posisi Long -0.0242%
Biaya inap posisi short 0.0085%
Waktu biaya inap 22:00 (UTC)
Spread 0.03

XRP/USD

0.40 Price
-0.480% 1D Chg, %
Biaya inap posisi Long -0.0500%
Biaya inap posisi short 0.0140%
Waktu biaya inap 22:00 (UTC)
Spread 0.00338

US100

12,494.30 Price
+0.240% 1D Chg, %
Biaya inap posisi Long -0.0189%
Biaya inap posisi short 0.0076%
Waktu biaya inap 22:00 (UTC)
Spread 1.8

Masih mencari broker yang bisa Anda percayai?

Bergabung dengan 485.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com

1. Buat & verifikasi akun Anda 2. Lakukan deposit 3. Temukan trading Anda